Biosynth extends peptide synthesis offering with Pepceuticals acquisition

Published: 5-Oct-2023

The acquisition of multi-kilogram GMP and fill-finish capabilities enables the support of all phases of the product life cycle from discovery to commercialisation

Biosynth, a supplier of critical materials to the life science industry, is pleased to  announce the acquisition of Pepceuticals, a UK producer of synthetic peptides with multi-kilogram GMP facilities and  fill-finish capabilities designed to support customers from clinical trials to commercial supply.  

Dr Urs Spitz, CEO and President of Biosynth, commented, “We are very excited for Pepceuticals to be joining Biosynth.  The Pepceuticals team has great expertise in optimizing the production of peptides and working at GMP and larger  scales, making it a natural fit for Biosynth as we round out our peptide offering."

Ehab Alramahy, Senior VIP, Head of Peptide Division, added “The acquisition of Pepceuticals into the  Biosynth family strengthens our position in the peptide field. As we've built the peptide division, our goal has always  been to offer a seamless, comprehensive service to our customers. The acquisition represents an important step which  allows us to extend our support to clinical trials and commercial supply.” 

“Joining the Biosynth Group marks the start of an exciting chapter for our team.” Dr. Kamal Badiani, Managing Director  of Pepceuticals, states, “We look forward to working together, combining our expertise and enhancing our offering to  our customers. We are excited to join Biosynth and provide leading peptide manufacturing services.”

You may also like